Tango Therapeutics (TNGX) Operating Leases (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Operating Leases of $30.0 million for Q1 2026, down 12.21% year-over-year from $34.1 million in Q1 2025, and down 2.84% quarter-over-quarter from $30.8 million in Q4 2025.
Tango Therapeutics (TNGX) Operating Leases (2020 - 2026) Analysis & Trends
Tango Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.
- In Q1 2026, Operating Leases fell 12.21% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $30.0 million (down 12.21% YoY), while the FY2025 annual figure was $30.8 million, down 9.42% from the prior year.
- Operating Leases for Q1 2026 stood at $30.0 million, down from $30.8 million in the prior quarter.
- The five-year high for Operating Leases was $39.9 million in Q3 2022, with the low at $30.0 million in Q1 2026.
- The 5-year median for Operating Leases is $35.5 million (2024), against an average of $35.3 million.
- The sharpest annual moves came in 2022 and 2026: Operating Leases soared 556.05% in 2022, then decreased 12.21% in 2026.
- Tango Therapeutics' Operating Leases stood at $39.4 million in 2022, then slipped by 6.41% to $36.8 million in 2023, then slipped by 7.6% to $34.0 million in 2024, then decreased by 9.42% to $30.8 million in 2025, then decreased by 2.84% to $30.0 million in 2026.
- Business Quant data shows TNGX's Operating Leases at $30.0 million in Q1 2026, $30.8 million in Q4 2025, and $31.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.05 Mn |
| Mar 31, 2026 | 29.96 Mn |
| Dec 31, 2025 | 30.83 Mn |
| Sep 30, 2025 | 31.66 Mn |
| Jun 30, 2025 | 32.47 Mn |
| Mar 31, 2025 | 34.12 Mn |
| Dec 31, 2024 | 34.04 Mn |
| Sep 30, 2024 | 34.76 Mn |
| Jun 30, 2024 | 35.47 Mn |
| Mar 31, 2024 | 36.17 Mn |
| Dec 31, 2023 | 36.84 Mn |
| Sep 30, 2023 | 37.47 Mn |
| Jun 30, 2023 | 38.08 Mn |
| Mar 31, 2023 | 38.74 Mn |
| Dec 31, 2022 | 39.36 Mn |
| Sep 30, 2022 | 39.95 Mn |
| Sep 30, 2021 | 6.09 Mn |
| Dec 31, 2020 | 6.93 Mn |